InsidersTradesSigma
申报总数
公司
▲ 买入（6 笔）
▼ 卖出（5 笔）
内部人交易记录
首席执行官已披露买入
6
已披露卖出
5
T+90 胜率
0%
T+90 平均收益
-1.7%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the complete record of transactions filed by Liu Suying, 首席执行官. Officer active across 5 companies, notably Mountain Crest Acquisition Corp. III. In total, 15 reports have been published. Breakdown: 6 buys · 5 sells. Total volume traded: €12.2m. Activity tracked since 20 May 2021. The latest transaction was disclosed on 30 December 2025 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Liu Suying
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报15 总计
385,714 股Ordinary sharesSEC:0001829126-26-006888:0
200,000 股@ US$5.0018.9% 占其流量Common StockSEC:0001829126-26-000026:0
100,000 股@ US$7.0011.9% 占其流量Common StockSEC:0001829126-25-001112:0
2,165,800 股Common StockSEC:0001829126-24-004708:0
1,840,800 股Common StockSEC:0001829126-23-002343:0
100,000 股@ US$10.0018.2% 占其流量Common StockSEC:0001829126-22-018181:0
200,000 股@ US$15.0046.5% 占其流量Common StockSEC:0001829126-22-009757:0
200,000 股@ US$12.5070.8% 占其流量Common StockSEC:0001104659-22-009714:0
2,086 股@ US$10.000.3% 占其流量Common StockSEC:0001104659-21-142581:0
标准退出：2021年9月12日 (T+90)
18,000 股@ US$10.003.5% 占其流量Common StockSEC:0001829126-21-014655:0
标准退出：2022年2月16日 (T+90)
205,000 股@ US$10.0040.1% 占其流量Common StockSEC:0001829126-21-014400:0
标准退出：2022年2月14日 (T+90)
14,250 股Common StockSEC:0000899243-21-042255:0
195,000 股@ US$10.0036.6% 占其流量Common StockSEC:0001104659-21-089830:0
标准退出：2021年9月30日 (T+90)
2,086 股@ US$10.000.5% 占其流量Common StockSEC:0001104659-21-082213:0
标准退出：2021年9月12日 (T+90)
110,000 股@ US$10.0028.5% 占其流量Common StockSEC:0001104659-21-071172:0
标准退出：2021年8月18日 (T+90)
15 条申报中的 15 条
About Liu Suying
Liu Suying is Chief Executive Officer and Chief Financial Officer. She has 15 filings in total, and within the sampled recent filings, purchases amount to EUR 4542819 and sales to EUR 7620172, from 2021-05-24 to 2026-06-25. Her filings concern Mountain Crest Acquisition Corp. V, Mountain Crest Acquisition Corp. III, Mountain Crest Acquisition Corp. IV, Mountain Crest Acquisition 6 Corp., and Better Therapeutics, Inc.
